Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabor E Linthorst

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Orphanet Journal of Rare Diseases|November 2, 2011
Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patientsBouwien E Smid, Saskia M Rombach, Johannes M F G Aerts, et al.
Hypertension (Dallas, Tex. : 1979)|August 8, 2012
Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosineSaskia M Rombach, Bas van den Bogaard, Eric de Groot, et al.
Plos One|October 25, 2012
Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcomeSaskia M Rombach, Johannes M F G Aerts, Ben J H M Poorthuis, et al.
Journal of Medical Genetics|March 22, 2015
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry diseaseDominique P Germain, Joel Charrow, Robert J Desnick, et al.
Clinical Journal of the American Society of Nephrology : CJASN|September 4, 2010
Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry RegistryChristoph Wanner, João P Oliveira, Alberto Ortiz, et al.
Clinical Chemistry|December 15, 2012
Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometryHenrik Gold, Mina Mirzaian, Nick Dekker, et al.
JIMD Reports|September 17, 2014
Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-upL van der Tol, David Cassiman, Gunnar Houge, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 2, 2011
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiationDavid G Warnock, Alberto Ortiz, Michael Mauer, et al.
Molecular Genetics and Metabolism|September 5, 2014
Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosisLinda van der Tol, Einar Svarstad, Alberto Ortiz, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 22, 2008
Elevated globotriaosylsphingosine is a hallmark of Fabry diseaseJohannes M Aerts, Johanna E Groener, Sijmen Kuiper, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Orphanet Journal of Rare Diseases|November 2, 2011
Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patientsBouwien E Smid, Saskia M Rombach, Johannes M F G Aerts, et al.
Hypertension (Dallas, Tex. : 1979)|August 8, 2012
Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosineSaskia M Rombach, Bas van den Bogaard, Eric de Groot, et al.
Plos One|October 25, 2012
Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcomeSaskia M Rombach, Johannes M F G Aerts, Ben J H M Poorthuis, et al.
Journal of Medical Genetics|March 22, 2015
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry diseaseDominique P Germain, Joel Charrow, Robert J Desnick, et al.
Clinical Journal of the American Society of Nephrology : CJASN|September 4, 2010
Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry RegistryChristoph Wanner, João P Oliveira, Alberto Ortiz, et al.
Clinical Chemistry|December 15, 2012
Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometryHenrik Gold, Mina Mirzaian, Nick Dekker, et al.
JIMD Reports|September 17, 2014
Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-upL van der Tol, David Cassiman, Gunnar Houge, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 2, 2011
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiationDavid G Warnock, Alberto Ortiz, Michael Mauer, et al.
Molecular Genetics and Metabolism|September 5, 2014
Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosisLinda van der Tol, Einar Svarstad, Alberto Ortiz, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 22, 2008
Elevated globotriaosylsphingosine is a hallmark of Fabry diseaseJohannes M Aerts, Johanna E Groener, Sijmen Kuiper, et al.
Pageof 7